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Methylseleninic acid promotes antitumour effects via nuclear
FOXO3a translocation through Akt inhibition
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Abstract
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Selenium supplement has been shown in clinical trials to reduce the risk of different cancers
including lung carcinoma. Previous studies reported that the antiproliferative and pro-apoptotic
activities of methylseleninic acid (MSA) in cancer cells could be mediated by inhibition of the
PI3K pathway. A better understanding of the downstream cellular targets of MSA will provide
information on its mechanism of action and will help to optimise its use in combination therapies
with PI3K inhibitors. For this study, the effects of MSA on viability, cell cycle, metabolism,
apoptosis, protein and mRNA expression, and Reactive Oxygen Species production were analysed
in A549 cells. FOXO3a subcellular localisation was examined in A549 cells and in stably
transfected human osteosarcoma U2foxRELOC cells. Our results demonstrate that MSA induces
FOXO3a nuclear translocation in A549 cells and in U2OS cells that stably express GFP-FOXO3a.
Interestingly, sodium selenite, another selenium compound, did not induce any significant effects
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on FOXO3a translocation despite inducing apoptosis. Single strand break of DNA, disruption of
tumour cell metabolic adaptations, decrease in ROS production, and cell cycle arrest in G1
accompanied by induction of apoptosis are late events occurring after 24 h of MSA treatment in
A549 cells. Our findings suggest that FOXO3a is a relevant mediator of the antiproliferative
effects of MSA. This new evidence on the mechanistic action of MSA can open new avenues in
exploiting its antitumour properties and in the optimal design of novel combination therapies. We
present MSA as a promising chemotherapeutic agent with synergistic antiproliferative effects with
cisplatin.

Keywords
Methylseleninic acid; Selenium; FOXO; Akt; PI3K; Cisplatin
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1. Introduction
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Lung cancer is a leading cause of cancer-related mortality and has one of the lowest cure
rate worldwide [1]. In early stages of the disease, surgery is the common choice while
chemotherapy is the main treatment in advanced lung cancer. The search for new synthetic
or natural drugs with low systemic toxicity and high efficiency holds great promise to
decrease the morbidity and mortality of cancer. The trace element selenium (Se) in various
chemical forms is nutritionally essential for humans but has toxic activity at higher levels [2,
3]. To date, the antioxidant and chemopreventive role of different Se agents as a dietary
supplement has not been completely elucidated [4]. Se compounds such as sodium selenite
(Na2SeO3) [5, 6] and methylseleninic acid (CH3SeO2H, abbreviated as MSA) have also
been studied as potential anticancer agents. MSA is a synthetic precursor of methylselenol
(CH3SeH) which induces several cellular, transcriptional and biochemical responses that
differ from those induced by selenium forms that are transformed via hydrogen selenide,
such as sodium selenite [7, 8].

Author Manuscript

As a constituent of the selenocysteine-containing selenoproteins, selenium has a key role in
redox regulation and defence against oxidative stress by greatly enhancing the activity of
some antioxidant enzyme systems [9]. Several selenoenzymes, including thioredoxin
reductase, iodothyronine deiodinase and glutathione peroxidase, may be associated with
cancer development and progression by modulating cell proliferation, transformation,
migration and protection against oxidative damage [2]. Selenium deficiency has also been
linked to cancer development since it was observed that populations with low selenium
intake had greater cancer incidence. Numerous studies and clinical trials have shown that
supranutritional doses of individual and mixed selenium compounds inhibit proliferation of
cancer cells, induce tumour cell apoptosis, suppress tumour formation and metastasis in
animal models and reduce the risk of prostate, lung, breast, and colorectal cancers in humans
[9–11]. However, not all selenium compounds have efficacy in chemoprevention, as in a
recent large clinical trial (SELECT), selenomethionine was concluded to be ineffective in
reducing the risk for prostate cancer development [12].
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Using a stable isotope-resolved metabolomic (SIRM) approach, Fan and collaborators [13]
reported that several metabolites, including lactate, glutathione and glutamate are depleted in
A549 lung cancer cells by selenite but not by selenomethionine, suggesting multiple
perturbations of the central metabolic networks. Interestingly, the reduction in glycolysis,
tricarboxylic acid cycle (TCA) and pentose phosphate pathway (PPP) fluxes observed is
opposite to those observed when phosphoinositide-3-kinase (PI3K) pathway is activated
[14], pointing to the hypothesis that Se agents target this signalling pathway. Among the
selenium compounds with anticancer properties, it has been reported that MSA is a potent
inhibitor of the growth and survival of human umbilical vein endothelial cells (HUVECs)
and that this antiproliferative effect could be enacted through the PI3K pathway [15, 16].
Studies with prostate cancer LNCaP, PC-3 (high basal Akt activity) and DU145 cells (low
basal Akt activity) have also shown that Akt plays an important role in regulating apoptosis
sensitivity to MSA [17]. However, the molecular mechanism of action of MSA is still not
fully elucidated.
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PI3K/Akt pathway has been shown to be activated in numerous tumours, including lung
cancer [18], as it is essential for cell proliferation and survival. Akt is a serine-threonine
kinase that is regulated via activation of PI3K. Forkhead box O (FOXO) transcription factors
are direct targets of Akt that modulate cellular differentiation, cell cycle, growth, survival,
apoptosis, metabolism, DNA repair, resistance to oxidative stress and tumour suppressor
pathways [19]. In mammals, FOXO1, FOXO3a and FOXO4 are ubiquitously expressed
while FOXO6 is expressed predominantly in neural cells. As transcription factors, FOXO
proteins activate or repress the transcription of their target genes through nuclear
translocation regulated by post-translational modifications such as phosphorylation,
acetylation and ubiquitination [20]. FOXO phosphorylation by Akt impairs its DNA binding
activity and promotes its interaction with the chaperone protein 14-3-3, resulting in nuclear
exclusion, cytoplasmic accumulation and ubiquitin-proteasome pathway-dependent
degradation, thus promoting cell survival. In contrast, FOXO proteins are activated and
released from 14-3-3 in the presence of oxidative stress through Jun N-terminal kinase
(JNK) signalling [19, 21, 22]. A hallmark of most cancers where the PI3K pathway is
hyperactivated (caused by RAS, PTEN or PI3K mutations) is inactivation of FOXO proteins
[23]. In contrast, PI3K depletion results in a significant activation of FOXO transcription
factors, induction of apoptosis, decrease of cell viability and G1 cell cycle arrest with
inhibition of CDK4/6, cyclin D and accumulation of p27 [24]. Therefore, the search for
compounds that promote activation and relocalisation of FOXO from the cytoplasm to the
nucleus is a promising therapeutic approach for cancer treatment and prevention [25].
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In this study, using A549 and U2foxRELOC cells expressing a GFP–FOXO3a fusion
protein, we have demonstrated that MSA induces FOXO3a dephosphorylation and nuclear
translocation. These findings provide a molecular mechanism to the cytotoxicity, apoptosis,
ROS detoxification, cell cycle arrest and metabolic changes observed in A549 cells and
implicate FOXO3a as a relevant mediator of MSA antitumour effects.
Moreover, since it has been reported that the antitumour effects of cisplatin are enhanced
when it is combined with FOXO nuclear export inhibitors [26–29] and that MSA
synergistically sensitised cancer cells in combination with certain chemotherapeutic drugs
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[30, 31], we hypothesised that combined treatment of MSA with cisplatin could be a
promising new strategy in cancer therapy.

2. Methods
All products were purchased from Sigma-Aldrich Co (St Louis, MO, USA), unless
otherwise specified.
2.1. Chemicals

Author Manuscript

MSA was supplied by Dr Fan (University of Kentucky, KY, USA). Sodium selenite was
purchased from Sigma-Aldrich. Stock solutions of 10 mM were prepared with Dulbecco’s
Phosphate Buffer Saline (PBS). The PI3K inhibitor LY294002 was purchased from
Calbiochem (San Diego, CA, USA), antibiotic (10 000 U mL−1 penicillin, 10 mg mL−1
streptomycin), PBS, Trypsin EDTA solution C (0.05% trypsin –0.02% EDTA) from
Biological Industries (Kibbutz Beit Haemet, Israel) and Fetal Bovine Serum (FBS) from
Invitrogen (Carlsbad, CA, USA).
2.2. Cell culture

Author Manuscript

Human lung carcinoma A549 cells (ATCC, Manassas, VA, USA) were grown in RPMI-1640
medium with L-glutamine and 10 mM D-Glucose prepared following the manufacturer’s
instructions. Human osteosarcoma stably transfected U2foxRELOC cells (a gift from Dr
Wolfgang Link), human osteosarcoma U2OS cells, human large cell lung cancer NCI-H460
cells, human ovary adenocarcinoma OVCAR3 cells, human embryonic kidney 293
(HEK293) cells and adipocyte-like differentiated 3T3-L1 cells (ATCC) were grown in
DMEM with L-glutamine and 25 mM D-Glucose. Human colorectal carcinoma HCT116
cells (ATCC) were cultured in DMEM:HAM F12 (1:1) with L-glutamine and 12.5 mM DGlucose. Human breast adenocarcinoma MCF7 cells (ATCC) were cultured in MEM
medium without phenol red (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA)
containing 10 mM D-glucose, 2 mM L-glutamine, 1 mM pyruvate (Biological Industries),
0.01 mg mL−1 insulin and 1% non-essential aminoacids (Biological Industries). Media were
supplemented with 10% heat-inactivated FBS, penicillin (50 U mL−1) and streptomycin (50
μg mL−1). U2foxRELOC cells, which express a resistance to Geneticin, were incubated with
G418 (Gibco) at 100 μg mL−1. 3T3-L1 pre-adipocyte cells were grown in DMEM with 0%
FBS, 10% NCS and 0.5% streptomycin/penicillin. Cells were incubated at 37°C in a
humidified atmosphere with 5% CO2.
2.3. 3T3-L1 differentiation
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Pre-adipocyte 3T3-L1 cells were seeded in 96-well-flat-bottomed microtitre plates. Medium
was changed two days after confluence with DMEM containing 0% NCS, 10% FBS and
induction cocktail (250 μM isobutylmethylxanthine, 1 μM dexamethasone and 0.98 μM
insulin). After 72 h, medium was replaced with 10% FBS DMEM containing 0.98 μM
insulin and cells were incubated for 72 h. Then, medium was replaced with 10% FBS
DMEM. Cells were fully differentiated into adipocytes within 48 h and cell viability assay
was performed on them.
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The assay was performed using a modified method described by Mosmann [32]. Increasing
concentrations of the inhibitor were added in sextuplicate in 96-well-flat-bottomed
microtitre plates where 2×103 A549 cells/well had been seeded 24 h before. MSA was added
to 3T3-L1 cells once the differentiation process was completed. MSA was depleted after >24
h of treatment, so media was refreshed every day. After 24, 48 or 72 hours, 1 mg mL−1 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS was added at a
final concentration of 0.5 mg mL−1. After 1 hour, supernatant was removed and the
formazan product was dissolved in 100 μL of dimethyl sulfoxide (DMSO). The absorbance
was measured on an ELISA plate reader (Tecan Sunrise MR20-301, TECAN, Salzburg,
Austria) at 550 nm. Concentrations that caused 50% of inhibition of cell growth (IC50) were
calculated using Graphpad Prism 6 software (La Jolla, CA, USA).
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2.5. Cell cycle analysis
5×104 A549 cells/well were seeded in 6-well plates and treated 24 hours later with MSA for
24, 48 and 72 hours. Both adherent and detached cells were collected by centrifugation after
trypsinisation, resuspended in 0.5 mL PBS and added dropwise to 4.5 mL 70% (v/v) cold
ethanol. Cells were stained in PBS containing 50 mg mL−1 propidium iodide (PI), 0.2 mg
mL−1 DNAse free RNAse (Roche, Basel, Switzerland) and 0.1% Triton X-100.
Fluorescence-activated cell sorter (FACS) analysis was carried out at 488 nm in an Epics XL
flow cytometer (Coulter Corporation, Hialeah, FL, USA). Data of 1×104 cells were collected
and analysed using Multicycle program (Phoenix Flow Systems, San Diego, CA, USA). All
experiments were performed three times with three replicates per experiment.
2.6. Apoptosis assay

Author Manuscript

Cells were seeded and treated as described in the cell cycle analysis assay. After
centrifugation, cells were washed and resuspended in binding buffer (10 mM Hepes pH 7.4,
140 mM sodium chloride, 2.5 mM calcium chloride). Annexin V coupled with fluorescein
isothiocyanate (FITC) was added according to the Annexin V-FITC kit (Bender System
MedSystem, Viena, Austria). Following 30 min of incubation at room temperature in
darkness, PI was added at 20 μg mL−1 1 min before FACS analysis. Experiments were
performed in triplicate and repeated three independent times. Data from 2×104 cells were
collected and analysed in each experiment.
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Apoptosis was also assessed using the membrane-permeable fluorescent dye bisbenzimide
Hoechst. After 24 h in the absence or presence of 72hIC50 MSA, cells were harvested by
mild trypsinisation, collected by centrifugation and fixed with 3.7% paraformaldehyde for
10 minutes at −20°C. Cells were washed with PBS, 0.5% Triton X-100 was added for 5 min
at 4°C and cells were stained with 50 ng mL−1 Hoechst 33342 dye for 15 min before placing
them onto slides and mounting the coverslips with Mowiol 4–88. Chromatin condensation
was visualised by fluorescence microscopy.
2.7. Single Cell Gel Electrophoresis (SCGE)
3×104 A549 cells/well were seeded in 6-well plates and treated the next day with 72hIC50
MSA, hydrogen peroxide 100 μM (positive control) and vehicle (negative control). After 24,
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.
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the comet assay was carried out according to Tice et al. [33]. Briefly, 6×105cells mL−1 were
mixed with 140 μL of 1% low-melting-point agarose and 70 μL were spread onto pre-coated
microscope slides (1% of normal-melting-point agarose). Glass cover slips (Menzel-Glaser,
Braunschweig, Germany) were placed on the gels, which were allowed to set at 4°C. Then,
cover slips were removed and cells embedded in agarose were lysed for 1 hour by
immersion in 2.5 M NaCl, 100 mM Na2-EDTA, 10 mM Trizma-HCl (pH 10) and 1% Triton
X-100 at 4°C. The slides were placed on a horizontal gel electrophoresis tank and the DNA
was allowed to unwind for 40 min in freshly prepared alkaline electrophoresis buffer (300
mM NaOH and 1 mM Na2-EDTA, pH > 13). Electrophoresis was carried out in the same
buffer for 30 min at 25 V in an ice bath condition. The slides were rinsed 3×5 min with 400
mM Trizma (pH 7.5) to neutralise the excess alkali, washed in water (10 minutes), stained
with 25 μL of 4,6-Diamidino-2-phenylindole (DAPI) (Invitrogen) and covered with a cover.
DAPI stained nuclei were evaluated with a Nikon Eclipse TE 300 fluorescence microscope
(Nikon, Tokyo, Japan). A total of 100 comets on each gel were visually scored and classified
as belonging to one of five classes according to the tail intensity. Each comet class was given
a value between 0 (undamaged) and 4 (maximum damage). Total score was calculated by the
following equation: (percentage of cells in class 0×0) + (percentage of cells in class 1×1) +
(percentage of cells in class 2×2) + (percentage of cells in class 3×3) + (percentage of cells
in class 4×4). Consequently, the total score was in the range from 0 to 400. Experiments
were performed in triplicate.
2.8. [U-13C]-glucose tracer experiments

Author Manuscript

A549 cells were seeded in 10 cm plates and grown in the RPMI medium as described above
for 24–36 h before the medium was changed to the RPMI medium with dialysed FBS and
[U-13C]-glucose, and in the absence (Control) or presence of 5 μM MSA. Cells in the tracer
medium were grown for another 24 hours before harvest by trypsinisation, followed by 2
washes in excess cold PBS to remove medium components. The final cell pellet obtained
from spin at 1700 g, 4°C for 5 min was flash-frozen in liquid N2 before extraction with icecold 10% trichloroacetic acid, as described previously [34]. The polar extracts were
aliquoted and lyophilised for analysis by GC-MS and 1D 13C-edited HSQC NMR at 14.1 T,
20°C using a 5 mm HCN triple resonance cold probe (Agilent Technologies, Santa Clara,
CA). For GC-MS analysis, the extracts were derivatised in MTBSTFA before analysis, and
for NMR analysis, the extracts were dissolved in 100% D2O, as described previously [35].
2.9. A549 transient transfection with FOXO3a-GFP reporter plasmid
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A549 cells were grown on the surface of cover slips (Menzel-Glaser, Braunschweig,
Germany) placed in 6-well plates. When confluence reached 80%, cells were transiently
transfected with a previously incubated (30 min) mix containing 2 μg of the GFP-FOXO3a
reporter plasmid and 2 μL of X-tremeGENE HP reagent (Roche) in 200 μL medium.
2.10. FOXO translocation assay
24 hours after seeding U2foxRELOC cells in 6-well plates containing cover slips or 21
hours after transfection in the case of A549 cells, media were replaced with media
containing MSA, sodium selenite, LY294002 20 μM (positive control) or vehicle (negative
control). After 6 hours of incubation, media were replaced with fresh media containing 1 μM
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.
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CellTracker Red (Invitrogen) and incubated for 10 minutes. Then, media were removed and
the cover slips containing the cells were washed 3×5 min with PBS, fixed with
paraformaldehyde for 15 minutes and washed again 3×5 min with PBS containing 20 mM
glycine. The cover slips were then mounted on slides using 20 μL ProLong Gold
(Invitrogen). After 16 h, the slides were visualised in a TCS SPE Leica confocal microscope
(Leica Microsystems, Wetzlar, Germany) and the intensity of the GFP fluorescence in nuclei
and cytoplasm was measured from a minimum of 50 random cells per condition using
ImageJ software (public domain National Institutes of Health, USA, http://rsbweb.nih.gov/
ij/).
2.11. Time course relocalisation assay and data analysis
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The U2foxRELOC-based assay was performed as described previously [36]. All liquid
handling for compound treatment, washing, fixing and staining steps was performed by a
robotic workstation [37]. Briefly, 1×105 cells mL−1 were seeded in black-walled clearbottomed 96-well microplates (BD Biosciences, San Jose, CA, USA) in a final volume of
200 μL/well using a multidrop automatic dispenser. After 12 h, cells were treated with 5 μM
MSA for 1.5, 3, 6, 11 or 24 hours and 10 μM LY294002 (positive control) and vehicle
(negative control) for 1.5 hours. Cells were washed with PBS, fixed in paraformaldehyde,
washed again and stained with DAPI for 20 min at room temperature to define the nucleus.
Assay plates were read on the BD Pathway 855 Bioimager (BD Biosciences) equipped with
a 488/10 nm EGFP excitation filter, a 380/10 nm DAPI excitation filter, a 515 LP nm EGFP
emission filter and a 435 LP nm DAPI emission filter. Images were acquired in the DAPI
and GFP channels of each well by using 20Q dry objective. Data was exported from the BD
Pathway Bioimager as text files and imported into the data analysis software BD Image Data
Explorer (BD Biosciences) for processing. Cells presenting nuclear accumulation of the
fluorescent reporter above 60% of the signal obtained from wells treated with 10 μM
LY294002 were considered as hits.
2.12. Total protein extraction
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3×105 A549 cells per well were seeded in 6-well plates and treated the next day with MSA,
sodium selenite, LY294002 or vehicle at the specified concentrations for 6 and 24 hours. At
the end of the treatment, cells were washed twice with ice-cold PBS, incubated for 30 min
on ice in lysis buffer containing 20 mM Trizma Base (pH 7.5), 1 mM dithriothreitol, 1 mM
EDTA, 0.0002% Triton X-100, 0.5 mM sodium deoxycholate, 0.4 mM PMSF, 1% protease
inhibitor cocktail and 1% phosphatase inhibitor cocktail (Thermo Scientific, Thermo Fisher
Scientific Inc., Waltham, MA, USA). Cells were scraped, sonicated and centrifuged at 16
000 g for 20 min at 4°C. Supernatants were recovered and the protein content was quantified
by the bicinchoninic acid (BCA) kit (Pierce Biotechnology, Rockford, IL, USA).
2.13. Cytosolic and nuclear protein extracts
A549 cells were cultured and treated as described in Total protein extraction section. In this
case, cells were incubated for 10 min on ice with hypotonic buffer containing 20 mM
HEPES (pH 7.6), 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 20% (v/v) glycerol, 0.1%
(v/v) Triton X-100, 1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail.
Cells were scraped and pipetted into cooled eppendorf tubes and then centrifuged at 1000
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.
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rpm in a swinging-bucket centrifuge at 4°C. Supernatant was the cytoplasmic extract and the
pellet contained the nuclei. To extract the nuclear proteins, the pellet was resuspended in five
times its volume with hypertonic buffer (hypotonic buffer adding 500 mM NaCl), rocked for
one hour at 4°C and spinned at maximum speed at 4°C for 5 min. The nuclear extract was
the supernatant. Both cytosolic and nuclear extracts were assayed for protein concentration
using the BCA kit.
2.14. Western blot analysis
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An equal volume of protein was size-separated by electrophoresis on SDS-polyacrylamide
gels and electroblotted onto polyvinylidene fluoride transfer membranes (PVDF) (Bio-Rad
Laboratories, Hercules, CA, USA). After 1 h of blocking at room temperature with 5% skim
milk in PBS 0.1% Tween, blots were incubated with the specific primary antibodies
overnight at 4°C. Then, membranes were treated with the appropriate secondary antibody for
1 h at room temperature. All blots were treated with Immobilon ECL Western Blotting
Detection Kit Reagent (EMD Millipore, Billerica, MA, USA) and developed after exposure
to an autoradiography film (VWR International, Radnor, PA, USA). The primary antibodies
used were Phospho-Akt (#9271), Akt (#9272), Phospho-mTOR (#5536) and procaspase 3
(#9662) from Cell Signaling (Beverly, MA, USA); FOXO3a (#06-951) from Upstate (EMD
Millipore); Phospho-FOXO3a (sc-101683), Phospho-JNK (sc-6254), FOXM1 (sc-500), Bax
(sc-493), CDK4 (sc-260), CDK6 (sc-177), ERK 2 (sc-154) and Lamin B (sc-6217) from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); Phospho-PRAS40 (#44-1100) from
BioSource International (Camarillo, CA, USA); PARP (#556493) and cytochrome c
(#556433) from BD Pharmingen (BD Biosciences); p27 (#610242) from BD Transduction
Laboratories (BD Biosciences) and β-actin (#69100) form MP Biomedicals (Santa Ana, CA,
USA).
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2.15. FOXO1 gene expression. RNA extraction, quantification, retrotranscription and
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

Author Manuscript

RNA was isolated from frozen plates using Trizol reagent (Invitrogen) following the
manufacturer’s instructions. Briefly, Trizol cell homogenates were mixed with chloroform
and centrifuged, obtaining an aqueous phase and an organic phase. In order to precipitate
RNA, cold isopropanol was added in the aqueous phase and centrifuged at 12 000 g for 15
min at 4°C. RNA was purified by several cold 75% ethanol washes and finally resuspended
in RNAse free water. RNA was quantified using a Nanodrop (ND 1000 V3.1.0, Thermo
Fisher Scientific Inc.). Reverse transcription was carried out with 1 μg RNA at 37°C for 1 h
with the following reagents: Buffer 5x (Invitrogen), DTT 0.1 M (Invitrogen), Random
Hexamers (Roche), RNAsin 40 U μL−1 (Promega, Fitchburg, WI, USA), dNTPs 40 mM
(Bioline, London, UK), M-MLV-RT 200 U μL−1 (Invitrogen). Gene expression analysis was
performed on an Applied Biosystems 7500 Real-Time PCR System according to the
manufacturer’s protocol, using Taqman gene specific sequences (FOXO1: Hs01054576_m1,
Applied Biosystems, Thermo Fisher Scientific Inc.). Reactions were performed in 20 μL
volume, using 9 μL of the cDNA mixture and 11 μL of the specific Taqman in Master Mix
(Applied Biosystems). Real-Time PCR was conducted according to the following
parameters: an initial incubation at 50°C for 2 min, a denaturalisation at 95°C for 10 min,
followed by 40 cycles at 95°C and 60°C for 15 s and 1 min, respectively. Expression was
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.
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quantified by ΔΔCt method using Cyclophilin A (PPIA: Hs99999904_m1, Applied
Biosystems) as reference gene.
2.16. Determination of Intracellular Reactive Oxygen Species (ROS) levels
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A549 cells were grown on 6-well plates to 70% confluence, washed once with warm PBS,
and incubated with 5 μM 2′-7′-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen)
in PBS supplemented with 5.5 mM glucose. After 30 min at 37°C, PBS was replaced with
complete culture medium and incubated for another 50 min at 37°C. Finally, cells were
trypsinised and resuspended thoroughly with 0.4 mL of PBS, H2DCFDA (50 μM) and PI (20
μg mL−1). Intracellular internalised probe reacts with ROS and emits fluorescence when
excited at 492 nm. Emitted fluorescence was recorded by flow cytometry at 520 nm using an
Epics XL flow cytometer (Coulter Corporation, Hialeah, FL, USA). Data of DCF
fluorescence concentrations from 1×104 PI negative cells were collected and analysed using
Multicycle program (Phoenix Flow Systems, San Diego, CA, USA).
2.17. Stable shRNA cell line generation
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U2OS and HEK293 stable FOXO3a knockdown cell lines were generated by Effectene
(Qiagen, Hilden, Germany) reagent-mediated transfection with three different FOXO3a
shRNA constructs originated from the Netherlands Cancer Institute (NKI) shRNA library
[38]. FOXO3a shRNA sequences FOXO3a KD#1
(GCAGGCCTCATCTCAGAGCTCTCTTGAAGCTCTGAGATGAGGCCTGC), FOXO3a
KD#2 (CTGCGACGGCTGACTGAAATCTCTTGAATTTCAGTCAGCAGTCGCAG) and
FOXO3a KD#3
(CCTGATGGGGGAAANANCTCTCTTGAANCTCTGANATGANGCCTGC) were cloned
into pRetroSuper vector (NKI, Amsterdam, Netherlands). Empty pRetroSuper vector was
used for control cells (Ctrl). Cells were selected in complete medium containing 1 μg mL−1
puromycin.
2.18. Data analysis and statistical methods
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Experiments were carried out at least in triplicate and repeated three times. To evaluate the
effects of combined drug treatments the multiple drug-effect analysis of Chou–Talalay [39]
was used with the CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA). MSA
interactions with cisplatin and carboplatin were quantified by determining the Combination
Index (CI), where CI<1, CI=1, and CI>1 indicate synergism, additivity, and antagonism,
respectively. All data are expressed as mean ± standard deviation (SD). Statistical analyses
were performed using Statgraphics statistical package (Statgraphics Centurion XVI,
StatPoint technologies Inc., Warrenton, VA, USA). Control and treatment measurements
were compared using Kruskal-Wallis, ANOVA and two-tailed independent sample Student’s
t tests. Differences were considered to be significant at p < 0.05.
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3. Results
3.1. MSA inhibits cell proliferation and causes G1 arrest in human lung carcinoma A549
cells
The effect of MSA on human lung carcinoma A549 cell proliferation was examined using
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric
viability assay. Significant dose-dependent growth inhibition was observed in this cell line
after treatment with 10 different concentrations of MSA for 24, 48 and 72 h (Figure 1A).
The MSA concentrations required for achieving a 50% growth inhibition on A549 cells after
24, 48 and 72 h of treatment (24hIC50, 48hIC50 and 72hIC50) were 2.2 ± 0.3 μM, 1.6 ± 0.2 and
1.3 ± 0.1 μM, respectively.
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Flow cytometric analyses of cell cycle distribution of A549 cells that had been exposed
to 72hIC50 MSA showed an increase of the G1 population at 24, 48 and 72 h of treatment as
compared to control cells (increasing by 41% at 72 h). With the same treatment, a
concomitant decrease was also observed in the percentage of cells in the S phase after 24, 48
and 72 h of treatment with respect to the untreated cells (38% decrease at 72 h), suggesting a
G0/G1 arrest (Figure 1B). A reduction in the percentage of cells in the G2 phase was also
observed at all times.
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The interphase cyclin-dependent kinases CDK4 and CDK6 control cell cycle re-entry and
progression through G1 phase. In response to mitogenic stimuli, CDK4/6-cyclin D
complexes phosphorylate the retinoblastoma (RB) protein family leading to their partial
inactivation and relieving the transcriptional repression mediated by the RB-E2F complex
[40]. Accordingly, MSA-induced cell cycle arrest could result from negative regulation of
CDK4/6-cyclin D complexes. To test this idea, CDK4 and CDK6 protein expression was
analysed after incubating A549 cells with 5 μM MSA for 6 h. A significant decrease in the
protein levels of CDK4/6 was observed in MSA-treated cells (Figure 1C).
To determine whether the concentrations of MSA used in the present study can acidify the
media, we measured the pH values before and after the addition of MSA at 1.3 and 5 μM
final concentrations. We also assessed the pH values after the addition of acetic acid, which
is a weak acid with an acid dissociation constant (Ka) of 1.8·10−5 and a similar molecular
structure as MSA. While the addition of acetic acid at 5 μM decreased the pH of the medium
by 0.5 units, the same concentration of MSA did not cause any significant effects. Therefore,
we conclude that the media were not acidified by the doses of MSA used in this study.
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3.2. MSA induces apoptosis in A549 cells
Apoptosis was assessed in A549 cells after 24, 48 and 72 h of treatment with 1.3 μM MSA
(72hIC50 for growth inhibition). FACS analysis using annexin V-FITC staining and PI
accumulation was performed to differentiate non-apoptotic cells (annexin V− and PI−), early
apoptotic cells (annexin V+ and PI−) and late apoptotic/necrotic cells (PI+).
To determine if MSA effects were specific or general to other selenium compounds, sodium
selenite was included in our analysis (Figure 2A). MSA treatment for 24 h caused no
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significant effect on A549 cell apoptosis, while at 48 and 72 h, MSA exposure generated an
increase in early apoptotic cells. In contrast, the apoptotic effect of sodium selenite was
visible at 24 h and greatly enhanced at 48 and 72 h (reaching around 40% for early apoptotic
cells) whereas the percentage of late apoptotic and necrotic cells remained constant at the
three time points. Therefore, the extent of apoptosis caused by MSA was much reduced
compared to that induced by sodium selenite, which can be due to different mechanisms of
apoptosis activation.
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Apoptotic cells undergo a series of characteristic morphological changes, such as shrinkage
of the cell, chromatin condensation, apoptotic body formation and internucleosomal
fragmentation of genomic DNA [41]. In order to evaluate DNA integrity, a single-cell gel
electrophoresis was performed (Comet assay). Single strand break of DNA was observed
after 24 h treatment with 1.3 μM MSA (Figure 2B). Total Comet score of treated and
untreated cells were 199 and 74, respectively. The presence of apoptotic bodies following 72
h MSA treatment at 72hIC50 concentration was detected by Hoechst 33342 staining (Figure
2C). Other typical apoptotic features such as rounding, shrinkage, detachment and loss of
contact with adjacent cells were observed in MSA-treated cells (Figure 2D) using an
inverted phase contrast microscope.
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Activation of the caspase pathway plays an important role in apoptosis. Caspases are
constitutive cysteine proteases that are normally present as inactive proenzymes. Their
enzymatic activity is induced during apoptosis in a self-amplifying cascade. Cleaved
upstream caspases (caspases 2, 8, 9 and 10) activate effector caspases (caspases 3, 6 and 7)
by proteolysis initiating the apoptotic cascade of events [41]. The intrinsic apoptosis
pathway involves the release of cytochrome c into cytosol and the formation of the
apoptosome complex by association with APAF-1. This complex activates caspase 9 which
in turn cleaves procaspase 3, implicated in the proteolysis of poly (ADP-ribose) polymerase
(PARP).
To elucidate the mechanisms involved in MSA or sodium selenite-mediated induction of
apoptosis in A549 cells, whole-cell lysates were extracted and Western blot analyses were
performed. The effects of LY294002, a known PI3K inhibitor [42], were also assessed. As
shown in Figure 2E, incubation with 5 μM MSA enhanced the expression of pro-apoptotic
Bax and cytosolic cytochrome c, decreased the level of procaspase 3 and caused PARP
cleavage. Sodium selenite 5 μM treatment induced changes in the same direction but to a
significantly lower extent (sodium selenite 72hIC50 in A549 cells is 5.5 ± 0.4 μM, data not
shown).
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3.3. MSA blocks glycolysis, TCA cycle and nucleotide biosynthesis
The effect of MSA on A549 cell metabolism was examined using the Stable IsotopeResolved Metabolomics (SIRM) approach [43–45]. A549 cells were treated with
uniformly 13C-labeled glucose ([U-13C]-glucose) in the absence (Control) or presence of 5
μM MSA for 24 h. The glucose transformation products were analysed by 1D HSQC NMR
and GC-MS, as shown in Figure 3. MSA-treated A549 cells had reduced synthesis of 13C
labelled lactate (glycolytic product), malate, aspartate, glutamate, citrate (TCA cycle
metabolites), as well as adenine and uracil nucleotides (with the ribose unit derived from the
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PPP), relative to untreated A549 cells. These results suggest that MSA attenuates the activity
of glycolysis, TCA cycle, PPP and/or nucleotide biosynthesis.
3.4. MSA causes nuclear translocation of FOXO3a in U2foxRELOC cells
Taking into account the arrest of cell cycle (G1), apoptosis induction, the metabolic effects
of MSA on A549 cells and their correlation with those described for the PI3K inhibition
[14], and the observed effects of MSA on PI3K signalling, we evaluated the effect of MSA
on FOXO factors known to be the major transcriptional downstream effecter proteins of the
PI3K/Akt signal transduction pathway [46]. As the activity of FOXO factors is mainly
regulated by their subcellular localisation [47], we first investigated if MSA induced FOXO
nuclear translocation. To this end we used U2foxRELOC cells, a previously established cell
system based on U2OS osteosarcoma cells that stably express a GFP–FOXO3a reporter [36,
48, 49].
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In order to select the optimal MSA concentration for analysing its effects on FOXO
translocation, the MSA 72hIC50 in U2foxRELOC cells was determined by incubating the
cells with 10 different concentrations of MSA for 72 h and performing colorimetric viability
assay. The values for dose-dependent growth inhibition were similar to the results obtained
for A549 cells (Figure 4C). We next analysed the spatio-temporal kinetics of FOXO nuclear
translocation upon MSA treatment. We exposed U2foxRELOC cells to 5 μM MSA for 1.5,
3, 6, 11 and 24 hours and determined subcellular localisation of the fluorescent FOXO
reporter protein. MSA treatment induced GFP-FOXO3a nuclear translocation from 1.5 to 24
h, reaching a maximum effect between 3 and 6 hours (data not shown).
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With the assay conditions optimised, U2foxRELOC cells were treated with 1.3 and 5 μM
MSA for 6 h and the subcellular localisation of GFP-FOXO3a was monitored by confocal
microscopy. Vehicle was used as a negative control and LY294002 (20 μM) as a positive
control. As shown in Figure 4A, GFP-FOXO3a was present in the cytosol of untreated cells
as well as in the nucleus, whereas in MSA- and LY294002-incubated cells GFP-FOXO3a
was localised almost exclusively in the nuclei. The percentage of cells in which GFPFOXO3a nuclear intensity was at least 3.5 times higher than GFP-FOXO3a cytoplasmic
intensity was less than 6% for control cells, more than 95% for LY294002-treated cells and
more than 94% for MSA-treated cells (at both concentrations) (Figure 4B). To determine
whether FOXO3a nuclear translocation was specifically driven by MSA or was a general
characteristic of selenium compounds, U2foxRELOC cells were also incubated with sodium
selenite at the same concentrations as MSA. The intracellular distribution of GFP-FOXO3a
remained unaltered in the presence of sodium selenite (Figure 4A). These results support our
hypothesis that MSA specifically induces FOXO3a nuclear translocation.
3.5. MSA induces GFP-FOXO3a nuclear translocation and increases nuclear FOXO3a in
A549 cells
To further confirm our hypothesis and test if the translocation effect of MSA is also relevant
for lung cancer cells, the effect of MSA on FOXO3a in A549 cells was analysed. To this
end, we transiently transfected GFP-FOXO into A549 cells and exposed them to MSA.
Figures 5A and 5B illustrate the results obtained after 6 h incubation with 5 μM MSA, 20
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μM LY294002 or vehicle. MSA induced nuclear accumulation of FOXO3a in A549 cells,
resulting in over 90% of cells exhibiting nuclear fluorescence intensity at least 1.5 times
greater than cytoplasmic fluorescence intensity, compared to less than 2.5% of cells for the
control conditions. To confirm the nuclear translocation of endogenous FOXO3a in nontransfected A549 cells in response to MSA treatment, Western blot assays of cells incubated
in the same conditions were performed. As shown in Figure 5C, MSA causes an increase in
nuclear FOXO3a concentration and a decrease in the levels of cytoplasmic phosphorylated
FOXO3a at the Ser253 residue (a known Akt phosphorylation site), consistent with our
aforementioned results.
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Since it is been described that FOXO1 transcription is stimulated by FOXO3a in a positive
feedback loop [50, 51], the effect of MSA on FOXO1 mRNA levels was analysed. Cells
were incubated with 5 μM MSA for different time periods from 1 h up to 24 h. Induction of
FOXO1 expression was detected from 2 h to 24 h and increased in a time-dependent manner
(Figure 5D).
To validate the results obtained with confocal microscopy of U2foxRELOC cells treated
with MSA and sodium selenite, the levels of active FOXO3a in non-transfected A549 cells
were analysed by Western blot. As shown in Figure 6, MSA induced FOXO3a expression
while sodium selenite caused its inhibition. To confirm this observation, FOXM1 protein
expression was examined, as previous studies have reported that FOXO3a is a negative
regulator of FOXM1 at the transcriptional level [52, 53]. In agreement with these
observations and further supporting MSA’s mode of action through FOXO3a activity, MSA
treatment significantly decreased FOXM1 expression while sodium selenite enhanced the
level of this transcription factor (Figure 6).
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In order to identify the mechanisms involved in FOXO subcellular redistribution, changes in
FOXO-regulating signal transduction pathways in response to MSA treatment were studied.
It was previously reported that cell cycle arrest induced by FOXO proteins is mediated by
enhanced transcription and protein expression of the cyclin-dependent kinase inhibitor p27
[54, 55] and reduced protein expression of cyclins D1 and D2 [56]. Both cases result in an
impaired capacity of CDK4 and CDK6 to hyperphosphorylate the RB protein family,
leading to G1 arrest [40]. Moreover, while FOXO3a has been reported to induce the
transcription of p27, PI3K/Akt pathway is known to suppress its expression in order to
proceed with cell cycle [57]. To investigate whether MSA-induced G1 cell cycle arrest is
associated with Akt and FOXO signalling, p27 and phosphorylation of Akt on Ser 473 status
were analysed by Western blot. Six-hour treatment with MSA (at both 1.3 and 5 μM)
significantly suppressed Akt phosphorylation without affecting its total protein level (Figure
6). These results suggest that FOXO3a dephosphorylation and nuclear accumulation in
response to MSA are mediated by Akt inactivation. The PI3K inhibitor LY294002 showed
the same behaviour as MSA while sodium selenite increased Akt phosphorylation in a dosedependent manner. The overactivation of Akt mediated by sodium selenite could account for
the depletion in FOXO3a levels observed (Figure 6). PRAS-40, an Akt substrate, followed
the same phosphorylation pattern, further supporting our hypothesis (Figure 6). mTOR
pathway was downregulated by MSA as phosphorylated mTOR levels were reduced
significantly after MSA treatment while sodium selenite activated this signalling pathway by
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increasing P-mTOR level. Dephosphorylation of Akt and FOXO activation preceded the
caspase-mediated apoptosis and the transcription of FOXO3a target genes such as p27
(Figure 6). As expected, p27 levels were notably increased after exposure to 5 μM MSA and
20 μM LY294002 for 24 h, even though p27 level was only slightly enhanced by exposure to
1.3 μM MSA. These data corroborate with previous results that showed MSA and sodium
selenite inducing distinct biochemical and cellular responses [7, 58, 59].
3.6. MSA elicits ROS detoxification
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FOXO proteins have been reported to induce detoxification of reactive oxygen species
(ROS) by up-regulating free radical scavenging enzymes, including manganese superoxide
dismutase and catalase [25]. FOXO transcription factors regulate two aspects of cellular
resistance to stress: repair of damages caused by ROS and detoxification of ROS [19]. Given
that MSA causes FOXO3a translocation to the nucleus, we measured ROS levels in A549
cells. The results show that 1.3 μM MSA caused a significant decrease in the levels of ROS
at 24 and 48 h (Figure 7). This decrease is consistent with the increased cellular free thiol
levels observed by Poerschke et al. [60] after 24 h MSA incubation. Cells incubated with
MSA for 72 h had similar ROS level to control cells. In contrast, sodium selenite inhibited
ROS production at 24 h but enhanced it at 48 and 72 h.
Previous studies described the role of JNK as a FOXO activator mediating the
phosphorylation of 14-3-3 proteins, thus releasing FOXO factors and trigging their nuclear
relocalisation [61–63]. As shown in Figure 6, MSA incubation resulted in an increase in PJNK, which is consistent with FOXO activation by Akt dephosphorylation. Sodium selenite
enhancement in P-JNK levels could be a consequence of selenite-induced ROS production
since JNK cascade can be independently activated by environmental stresses [64].
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3.7. FOXO3a knockdown attenuates MSA effects
In order to confirm the role of FOXO3a as a mediator of MSA antitumour effects, we stably
silenced FOXO3 in two different cell lines using shRNA vectors. We established U2OS and
HEK293 cells that stably expressed three different hairpin sequences and validated the
efficiency of FOXO3a knockdown by Western blot. The results revealed that FOXO3a KD#1
construct exhibited the strongest knockdown effect, followed by FOXO3a KD#2 (Figure
8A). Hence, the U2OS cell lines transfected with these two constructs and the FOXO3a
KD#1 HEK293 cell line were selected to perform the following experiments.
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We incubated Ctrl (empty vector) and FOXO3a knockdown cells with 1 μM MSA or vehicle
(PBS) and measured cell proliferation, cell cycle and apoptosis after 72 h (Figure 8B–G),
and ROS after 48 h treatment (Figure 8H–I). The results showed that MSA effects were
attenuated or even abolished by FOXO3a knockdown. In fact, the observed antiproliferative
effect of MSA was significantly reduced after FOXO3a inhibition, while no differences in
cell cycle, apoptosis and ROS levels were found between untreated and MSA-treated
FOXO3a knockdown cells. These results further confirm that the antitumour response of
MSA treatment is mediated by FOXO3a.
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Cisplatin-based therapy is a conventional chemotherapeutic treatment for cancer. However,
its clinical efficacy is compromised by acquired resistance and dose-limiting side effects
[65]. Consequently, the search for combination therapies and chemosensitising agents to
cisplatin is essential for improving its treatment outcome. Given that previous studies
reported the enhancement of cisplatin’s antitumour effects in combination with FOXO
nuclear export inhibitors [26–29], we hypothesised that combined treatment of MSA with
cisplatin could be a promising new strategy in cancer therapy.

Author Manuscript

To quantify the synergy of dose-dependent effect on cell viability, we used the Combination
Index (CI) equation of Chou and Talalay [39]. We examined the synergistic effects of MSA
and cisplatin in A549, HCT116 (colorectal carcinoma), MCF7 (breast adenocarcinoma) and
OVCAR3 (ovary adenocarcinoma) cells which are considered to present cisplatin-resistance,
exhibiting IC50 values higher than 10 μM [66] (http://www.cancerrxgene.org/translation/
Drug/1005). The combination of MSA and cisplatin treatment in a wide dose range showed
a significant synergism in the antiproliferative effects with a CI<1 in each tested cell line
(Table 1).
In addition, we studied the synergism of MSA and carboplatin, a derivative of cisplatin
commonly used in conventional chemotherapy with similar efficacy, in the same cell lines.
Likewise, the combination of MSA and carboplatin treatment in a wide dose range exhibited
a synergistic (CI<1) antiproliferative effect in each tested cell line (Table 2).
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Compared with cisplatin or carboplatin single treatments, dosage of these conventional
chemotherapeutics could be remarkably reduced in combination therapy with MSA to gain
the same inhibitory effect on cell proliferation. Therefore, the synergism observed in
HCT116, MCF7, A549 and OVCAR3 cells suggests the combined MSA / cisplatin or
carboplatin treatment as an efficient strategy to decrease the chemotherapeutic doses and
consequently, mitigate the overall toxicity.
In order to determine if MSA treatment obtained similar growth inhibitory results in other
cancer cell lines, the effect of MSA on cell viability in NCI-H460 (large cell lung cancer)
and HCT116 (colorectal carcinoma) cell lines was measured. The 72hIC50 values obtained
were in the same range as for A549 cells, being 1.7 ± 0.2 μM and 1.9 ± 0.2 μM for NCIH460 and HCT116 cells, respectively (Figure 9A). To investigate if FOXO activation
mediated by MSA is a general mechanism and not cell-dependent, HCT116 cell line was
used to evaluate FOXO1 mRNA expression, which showed a significant increase in a timedependent manner beginning at 2 h with 5 μM MSA treatment (data not shown).
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To test the selective cytotoxicity of MSA for cancer cells, a MTT colorimetric viability assay
using a non-tumour non-proliferating cell line was performed. Differentiated 3T3-L1
adipocytes were incubated for 72 h with 9 different MSA concentrations and the effect on
cell proliferation and the 72hIC50 value were determined (Figure 8A). 72hIC50 for MSA in
3T3-L1 cells was three to five times the value for all tumour cell lines that have been studied
(Figure 9B), supporting MSA as a promising chemotherapeutic agent with selective
antiproliferative effects on cancer cells.
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4. Discussion
Selenium is an essential trace element fundamental to human health with pivotal structural
and enzymatic functions in selenoproteins. Selenium deficiency has been acknowledged as a
contributing factor to a series of distinct pathophysiological conditions, including cancer.
Several selenium compounds have shown cancer chemopreventive and chemotherapeutic
activities in both animal models and humans [11, 67, 68]. It is important to note that both
dose and chemical form of selenium are crucial for the antitumour activity. MSA and
sodium selenite are among the forms with high anticarcinogenic activity while
selenomethionine used in the SELECT trial was ineffective in cancer prevention in humans
[11, 69, 70].
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There are several in vivo studies involving dietary selenium supplementation for cancer
therapy and prevention. The evaluation of the effects of different diets containing MSA,
sodium selenite or selenomethionine in tumour xenografts in mice has led to the conclusion
that MSA exhibits a superior in vivo inhibitory efficacy against human prostate and breast
cancers over selenomethionine or sodium selenite [8, 10, 71]. Indeed, dietary
supplementation with MSA significantly inhibits xenograft tumour growth and reduces
angiogenesis and spontaneous metastasis [8, 10, 71–73]. Importantly, supplementation with
MSA does not affect neither the animal body weight nor the food consumption when
compared with control diet animals, and histological alterations in organs are not observed,
altogether indicating a good tolerance to the used dosage of MSA without adverse side
effects [8, 71, 72]. Moreover, MSA supplementation results in less accumulation of selenium
both in liver and primary tumour when compared with selenomethionine, while causes no
increment in kidney selenium levels relative to controls [8, 10, 71]. These results are
consistent with the fact that MSA is efficiently transformed into methylselenol which in turn
can be methylated and excreted [74]. Therefore, MSA treatment presents superior in vivo
antitumour efficacy with good tolerance results over other selenium derivates [8, 10, 71, 72].
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The fact that the molecular mechanism underlying MSA’s antitumour properties has not
been fully elucidated is a bottle neck in designing combination therapies with MSA. In this
study, we described that lung carcinoma A549 cells are very sensitive to MSA treatment, in
terms of growth inhibition, cell cycle arrest in G1 phase, attenuated intracellular ROS levels
and apoptosis. However, some studies have described selenium derivatives as pro-oxidant
products at higher doses than those used in this study [13]. This property could be due to
dose dependence: at low concentrations MSA could serve as an antioxidant product, while at
higher concentrations it could act as a pro-oxidant compound [69]. The antioxidant function
could be mediated via the synthesis of selenocysteine, which is an essential residue of
important ROS-detoxifying selenoproteins, such as glutathione peroxidases, thioredoxin
reductases and possibly selenoprotein P [75]. Our results suggest distinct redox modulations
of the two selenocompounds tested and thus different mechanisms of action. Heightened
levels of ROS generated by sodium selenite can cause damage to DNA and mitochondria,
leading to apoptosis. Considering these and previous results [6], sodium selenite induces
apoptosis through generation of ROS while MSA-mediated apoptosis is regulated by a
different molecular pathway like FOXO activation.
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We have also shown that MSA induces FOXO translocation to the nucleus after 1.5 h of a 5
μM treatment and this localisation is maintained for at least 24 h. In addition, we have
demonstrated that FOXO translocation after 1.5 h is the early event that occurs before the
observed molecular and metabolic effects of MSA. Moreover, we have shown that the
inhibition of the PI3K pathway through Akt and FOXO3a dephosphorylation could be the
molecular mechanism underlying inhibition of cell proliferation, disruption of tumour cell
metabolic adaptations, induction of apoptosis, ROS detoxification and cell cycle arrest in
A549 cells. Indeed, FOXO3a knockdown attenuated or even abolished the antiproliferative
effects of MSA. It is worth noting that although MSA activity is mediated through inhibition
of Akt, it does not have an effect on other signalling pathways such as MAPK [7].
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FOXO proteins are potentially key targets for new therapeutic strategies for blocking
tumourigenesis due to their ability to control cell cycle and promote apoptosis [76]. The
tumour suppressor properties of FOXO factors are inhibited mostly by overactivation of their
inhibitory signalling, in contrast to other tumour suppressors, whose activities are abrogated
by genetic or epigenetic changes. These characteristics call for strategies on rescuing FOXO
activity by its reactivation and targeting of its inhibitors [25]. As such, MSA is well-suited to
serve as an anticancer agent by inhibiting the PI3K/Akt/mTOR axis and activating JNK
signalling pathway, leading to FOXO nuclear relocalisation and restoration of its gene
expression. Moreover, combination therapies that target PI3K/Akt pathway and promote
nuclear FOXO retention are considered to be a promising approach to treat several tumour
types. For example, in recent studies it has been proposed that cytotoxicity of cisplatin in
sensitive cells can be enhanced and drug resistance in unresponsive cells reversed by using
agents that target the PI3K/Akt/FOXO pathway in combination with cisplatin [26–29]. Our
studies support such hypothesis as MSA both synergised with cisplatin and its derivative
carboplatin in blocking A549, HCT116, MCF7 and OVCAR3 cell proliferation. Thus, the
combination of MSA with either cisplatin or carboplatin could represent a promising new
approach to lung cancer treatment in terms of reducing platinum derivatives doses or toxicity
as well as drug resistance.

5. Conclusions
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Our data support a strong antiproliferative action of MSA in the low micromolar range on
A549 cells, which is mediated by blocking G1 progression and triggering apoptosis. These
MSA effects are associated with the inhibition of the Akt pathway, leading to
dephosphorylation of FOXO proteins and their nuclear translocation, which in turn activate
the expression of FOXO target genes. The time course data suggest that FOXO
dephosphorylation and relocalisation to the nucleus are early events that activate the
antiproliferative response of A549 cells to MSA. By targeting the PI3K/Akt/FOXO pathway,
MSA could synergise with cisplatin in combination therapy to reduce the commonly
observed toxicity and resistance development of cisplatin-based chemotherapy.
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MSA

Methylseleninic acid

Se

Selenium

PPP

Pentose Phosphate Pathway

TCA

Tricarboxylic acid

ROS

Reactive Oxygen Species

1D HSQC

One Dimension Heteronuclear Single Quantum Coherence

1H-NMR

Proton Nuclear Magnetic Resonance

72hIC
50

Concentration that caused 50% of inhibition of cell growth at 72 h of
treatment

FOXO

Forkhead box O

FOXM1

Forkhead box protein M1

Akt

Protein kinase B

PI3K

Phosphoinositide-3-kinase

mTOR

mammalian Target of Rapamycin

CDK

Cyclin-dependent kinase

JNK

Jun N-terminal kinase

Bax

B-cell lymphoma-2-associated X protein

PARP

Poly (ADP-ribose) polymerase

PRAS40

Proline-rich Akt substrate 40 kDa

ERK2

Extracellular signal-regulated kinase 2

References
Author Manuscript

1. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and
mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014
2. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention:
complexities with thioredoxin reductase. Carcinogenesis. 1999; 20:1657–66. [PubMed: 10469608]
3. Schrauzer GN. Selenium and selenium-antagonistic elements in nutritional cancer prevention.
Critical reviews in biotechnology. 2009; 29:10–7. [PubMed: 19514899]
4. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O. Selenium or No Selenium- That Is the
Question in Tumor Patients: A New Controversy. Integrative Cancer Therapies. 2010; 9:136–41.
[PubMed: 20462857]

Pharmacol Res. Author manuscript; available in PMC 2016 April 28.

Tarrado-Castellarnau et al.

Page 19

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

5. An JJ, Shi KJ, Wei W, Hua FY, Ci YL, Jiang Q, et al. The ROS/JNK/ATF2 pathway mediates
selenite-induced leukemia NB4 cell cycle arrest and apoptosis in vitro and in vivo. Cell Death and
Disease. 2013; 4:e973. [PubMed: 24357804]
6. Park SH. Induction of apoptosis and autophagy by sodium selenite in A549 human lung carcinoma
cells through generation of reactive oxygen species. Toxicology Letters. 2012; 212:252–61.
[PubMed: 22721804]
7. Jiang C, Wang Z, Ganther H, Lü J. Distinct effects of methylseleninic acid versus selenite on
apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Molecular
Cancer Therapeutics. 2002; 1:1059–66. [PubMed: 12481429]
8. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, et al. Superior in vivo inhibitory efficacy of
methylseleninic acid against human prostate cancer over selenomethionine or selenite.
Carcinogenesis. 2008; 29:1005–12. [PubMed: 18310093]
9. Patrick L. Selenium biochemistry and cancer: a review of the literature. Altern Med Rev. 2004;
9:239–58. [PubMed: 15387717]
10. Chen YC, Prabhu KS, Das A, Mastro AM. Dietary selenium supplementation modifies breast
tumor growth and metastasis. Int J Cancer. 2013; 133:2054–64. [PubMed: 23613334]
11. Sharma AK, Amin S. Post SELECT: selenium on trial. Future Med Chem. 2013; 5:163–74.
[PubMed: 23360141]
12. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of
selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). JAMA. 2009; 301:39–51. [PubMed: 19066370]
13. Fan TW, Higashi RM, Lane AN. Integrating metabolomics and transcriptomics for probing SE
anticancer mechanisms. Drug Metab Rev. 2006; 38:707–32. [PubMed: 17145697]
14. Robey RB, Hay N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and
oncogenesis. Seminars in cancer biology. 2009; 19:25–31. [PubMed: 19130886]
15. Wang Z, Jiang C, Ganther H, Lu J. Antimitogenic and proapoptotic activities of methylseleninic
acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK
signaling. Cancer Res. 2001; 61:7171–8. [PubMed: 11585751]
16. Wu Y. Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Molecular Cancer Therapeutics. 2006; 5:246–52. [PubMed: 16505097]
17. Hu H, Jiang C, Li G, Lu J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by
methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis. 2005; 26:1374–81.
[PubMed: 15845651]
18. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B, et al. Overexpression of
phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg. 2001; 386:293–301.
[PubMed: 11466572]
19. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor
suppression. Oncogene. 2005; 24:7410–25. [PubMed: 16288288]
20. Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional
harmony. Nat Rev Cancer. 2013; 13:482–95. [PubMed: 23792361]
21. Eijkelenboom A, Burgering BMT. FOXOs: signalling integrators for homeostasis maintenance.
Nature Reviews Molecular Cell Biology. 2013; 14:83–97. [PubMed: 23325358]
22. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008; 27:2276–88. [PubMed: 18391970]
23. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene.
2005; 24:7455–64. [PubMed: 16288292]
24. Reagan-Shaw S. RNA Interference-Mediated Depletion of Phosphoinositide 3-Kinase Activates
Forkhead Box Class O Transcription Factors and Induces Cell Cycle Arrest and Apoptosis in
Breast Carcinoma Cells. Cancer Research. 2006; 66:1062–9. [PubMed: 16424042]
25. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research. 2011; 1813:1978–86. [PubMed: 21440011]
26. Fernandez de Mattos S, Villalonga P, Clardy J, Lam EW. FOXO3a mediates the cytotoxic effects of
cisplatin in colon cancer cells. Mol Cancer Ther. 2008; 7:3237–46. [PubMed: 18852127]

Pharmacol Res. Author manuscript; available in PMC 2016 April 28.

Tarrado-Castellarnau et al.

Page 20

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

27. Cortés R, Tarrado-Castellarnau M, Talancón D, López C, Link W, Ruiz D, et al. A novel
cyclometallated Pt(ii)–ferrocene complex induces nuclear FOXO3a localization and apoptosis and
synergizes with cisplatin to inhibit lung cancer cell proliferation. Metallomics. 2014; 6:622.
[PubMed: 24492855]
28. Liu H, Yin J, Wang C, Gu Y, Deng M, He Z. FOXO3a mediates the cytotoxic effects of cisplatin in
lung cancer cells. Anticancer Drugs. 2014; 25:898–907. [PubMed: 24814195]
29. Fang L, Wang H, Zhou L, Yu D. FOXO3a reactivation mediates the synergistic cytotoxic effects of
rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicology and Applied
Pharmacology. 2011; 251:8–15. [PubMed: 21092744]
30. Yin S, Dong Y, Li J, Fan L, Wang L, Lu J, et al. Methylseleninic acid potentiates multiple types of
cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis. 2011; 17:388–
99. [PubMed: 22179721]
31. Hu H, Jiang C, Ip C, Rustum YM, Lu J. Methylseleninic acid potentiates apoptosis induced by
chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res. 2005;
11:2379–88. [PubMed: 15788689]
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation
and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63. [PubMed: 6606682]
33. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/
comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen.
2000; 35:206–21. [PubMed: 10737956]
34. Fan, TW. The Handbook of Metabolomics. New York: 2012. Considerations of Sample Preparation
for Metabolomics Investigation; p. 7-27.
35. Lane AN, Fan TW, Higashi RM. Isotopomer-based metabolomic analysis by NMR and mass
spectrometry. Methods Cell Biol. 2008; 84:541–88. [PubMed: 17964943]
36. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Chemical genetic analysis of FOXO nuclearcytoplasmic shuttling by using image-based cell screening. Chembiochem. 2008; 9:2229–37.
[PubMed: 18756565]
37. Rosado A, Zanella F, Garcia B, Carnero A, Link W. A dual-color fluorescence-based platform to
identify selective inhibitors of Akt signaling. PloS one. 2008; 3:e1823. [PubMed: 18350159]
38. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, et al. A largescale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004;
428:431–7. [PubMed: 15042092]
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27–55. [PubMed: 6382953]
40. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting Cell Cycle Regulation
in Cancer Therapy. Pharmacol Ther. 2013; 138:255–71. [PubMed: 23356980]
41. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 2000;
45:528–37. [PubMed: 10728374]
42. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). The Journal of biological
chemistry. 1994; 269:5241–8. [PubMed: 8106507]
43. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of
metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved
metabolomics (SIRM). Mol Cancer. 2009; 8:41. [PubMed: 19558692]
44. Fan TW, Lane AN, Higashi RM, Yan J. Stable isotope resolved metabolomics of lung cancer in a
SCID mouse model. Metabolomics. 2011; 7:257–69. [PubMed: 21666826]
45. Fan TW, Yuan P, Lane AN, Higashi RM, Wang Y, Hamidi AB, et al. Stable isotope-resolved
metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions.
Metabolomics. 2010; 6:165–79. [PubMed: 20631920]
46. Zanella F, Link W, Carnero A. Understanding FOXO, new views on old transcription factors. Curr
Cancer Drug Targets. 2010; 10:135–46. [PubMed: 20088800]
47. Zanella F, dos Santos NR, Link W. Moving to the Core: Spatiotemporal Analysis of Forkhead Box
O (FOXO) and Nuclear Factor-κB (NF-κB) Nuclear Translocation. Traffic. 2013; 14:247–58.
[PubMed: 23231504]
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.

Tarrado-Castellarnau et al.

Page 21

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

48. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A, et al. Chemical Interrogation
of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3Kinases. Journal of Biological Chemistry. 2009; 284:28392–400. [PubMed: 19690175]
49. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Using multiplexed regulation of luciferase
activity and GFP translocation to screen for FOXO modulators. BMC Cell Biology. 2009; 10:14.
[PubMed: 19243599]
50. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The Transcription of FOXO Genes Is
Stimulated by FOXO3 and Repressed by Growth Factors. Journal of Biological Chemistry. 2009;
284:10334–42. [PubMed: 19244250]
51. Fang L, Wang H, Zhou L, Yu D. Akt-FOXO3a signaling axis dysregulation in human oral
squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy. Oral Oncology.
2011; 47:16–21. [PubMed: 21109483]
52. Yung MM, Chan DW, Liu VW, Yao KM, Ngan HY. Activation of AMPK inhibits cervical cancer
cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013; 13:327.
[PubMed: 23819460]
53. Jiang L, Cao XC, Cao JG, Liu F, Quan MF, Sheng XF, et al. Casticin induces ovarian cancer cell
apoptosis by repressing FoxM1 through the activation of FOXO3a. Oncol Lett. 2013; 5:1605–10.
[PubMed: 23761826]
54. Medema RH, Kops GJPL, Bos JL, Burgering BMT. AFX-like Forkhead transcription factors
mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000; 404:782–7.
[PubMed: 10783894]
55. Li CJ, Chang JK, Chou CH, Wang GJ, Ho ML. The PI3K/Akt/FOXO3a/p27Kip1 signaling
contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts. Biochemical
Pharmacology. 2010; 79:926–37. [PubMed: 19883628]
56. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJPL, Lam EWF, et
al. Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of
Cyclin D. Molecular and cellular biology. 2002; 22:7842–52. [PubMed: 12391153]
57. Liang J, Slingerland JM. Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle
Progression. Cell Cycle. 2003; 2:336–42.
58. Li GX, Hu H, Jiang C, Schuster T, Lü J. Differential involvement of reactive oxygen species in
apoptosis induced by two classes of selenium compounds in human prostate cancer cells.
International Journal of Cancer. 2007; 120:2034–43. [PubMed: 17230520]
59. de Miranda JX, Andrade FD, Conti AD, Dagli ML, Moreno FS, Ong TP. Effects of selenium
compounds on proliferation and epigenetic marks of breast cancer cells. J Trace Elem Med Biol.
2014; 28:486–91. [PubMed: 25087768]
60. Poerschke RL, Franklin MR, Moos PJ. Modulation of redox status in human lung cell lines by
organoselenocompounds: Selenazolidines, selenomethionine, and methylseleninic acid.
Toxicology in Vitro. 2008; 22:1761–7. [PubMed: 18768157]
61. Wang X, Chen WR, Xing D. A pathway from JNK through decreased ERK and Akt activities for
FOXO3a nuclear translocation in response to UV irradiation. Journal of Cellular Physiology. 2012;
227:1168–78. [PubMed: 21604264]
62. Sunayama J. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. The
Journal of cell biology. 2005; 170:295–304. [PubMed: 16009721]
63. Sunters A. Paclitaxel-Induced Nuclear Translocation of FOXO3a in Breast Cancer Cells Is
Mediated by c-Jun NH2-Terminal Kinase and Akt. Cancer Research. 2006; 66:212–20. [PubMed:
16397234]
64. Zou Y, Niu P, Yang J, Yuan J, Wu T, Chen X. The JNK signaling pathway is involved in sodiumselenite-induced apoptosis mediated by reactive oxygen in HepG2 cells. Cancer Biol Ther. 2008;
7:689–96. [PubMed: 18728404]
65. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. European
Journal of Pharmacology. 2014; 740:364–78. [PubMed: 25058905]
66. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic
identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483:570–5.
[PubMed: 22460902]

Pharmacol Res. Author manuscript; available in PMC 2016 April 28.

Tarrado-Castellarnau et al.

Page 22

Author Manuscript
Author Manuscript

67. Micke O, Schomburg L, Buentzel J, Kisters K, Muecke R. Selenium in oncology: from chemistry
to clinics. Molecules (Basel, Switzerland). 2009; 14:3975–88.
68. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action.
The Proceedings of the Nutrition Society. 2005; 64:527–42. [PubMed: 16313696]
69. Drake EN. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med
Hypotheses. 2006; 67:318–22. [PubMed: 16574336]
70. Vinceti M, Dennert G, Crespi CM, Zwahlen M, Brinkman M, Zeegers MP, et al. Selenium for
preventing cancer. Cochrane Database Syst Rev. 2014; 3:CD005195. [PubMed: 24683040]
71. Yan L, DeMars LC. Dietary supplementation with methylseleninic acid, but not selenomethionine,
reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int J Cancer. 2012; 131:1260–6.
[PubMed: 22095442]
72. Zeng H, Wu M. The Inhibitory Efficacy of Methylseleninic Acid Against Colon Cancer Xenografts
in C57BL/6 Mice. Nutrition and cancer. 2015:1–8.
73. Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, et al. Methylseleninic acid inhibits microvascular
endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer. 2008;
122:15–24. [PubMed: 17847021]
74. Ganther HE. Pathways of Selenium Metabolism Including Respiratory Excretory Products.
International Journal of Toxicology. 1986; 5:1–5.
75. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochimica
et biophysica acta. 2009; 1790:1478–85. [PubMed: 19268692]
76. Link W. FOXO proteins as potential targets for anticancer therapy. Current Drug Targets. 2011;
12:1232–4. [PubMed: 21443469]

Author Manuscript
Author Manuscript
Pharmacol Res. Author manuscript; available in PMC 2016 April 28.

Tarrado-Castellarnau et al.

Page 23

Author Manuscript
Author Manuscript

Figure 1. MSA effects on cell viability and cell cycle in A549 cells

Author Manuscript

A. Growth inhibition of MSA on A549 lung cancer cells after 24, 48 and 72 h measured by
MTT assay. Exponentially growing cells were treated with the indicated concentration of
MSA for 24, 48 and 72 h. The assay was carried out using six replicates and repeated three
times. Data are represented as mean ± SD. B. Cell cycle analysis of MSA-treated cells.
A549 cells treated for 24, 48, 72 hours with 1.3 μM MSA presented a G1 arrest. Cell cycle
analysis was conducted after propidium iodide staining. Values represent mean ± SD and
statistically significant differences between treated and control cells at p < 0.05 are indicated
with an asterisk (*). C. Western blot analysis showed a significant CDK4 and CDK6
inhibition at 6 h treatment with 5 μM MSA. Protein expression levels were quantified using
ImageJ software and are expressed as mean band intensity normalised to β-actin and relative
to control condition (*, p < 0.05).
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Figure 2. Apoptosis assays in A549 cells

Author Manuscript

A. Flow cytometry analysis of Annexin V-FITC staining and propidium iodide accumulation
after exposure of A549 cells to MSA and sodium selenite at their respective 72hIC50
concentrations for 24, 48 and 72 hours. PI staining at 488 nm is represented on the y axis
and annexin V-FITC staining at 488 nm on the x axis. Quadrant 4 (PI–/FITC−) represents
non-apoptotic cells, early apoptosis is shown in right bottom quadrant (PI–/FITC+) and
quadrants 1 and 2 (PI+) depict late apoptotic/necrotic cells. Plots illustrate the percentage of
cells in early apoptosis and late apoptosis/necrosis. Values are expressed as mean ± SD of
three experiments in triplicate. Differences between treated and control groups were
considered statistically significant at p < 0.05 (*). B. DAPI staining of A549 cells DNA after
electrophoresis in agarose gel (single-cell gel electrophoresis, Comet Assay). Control
condition treatment with vehicle showed no induction of single strand breaks while 24 h
MSA exposure at 72hIC50 concentration caused DNA fragmentation in A549 cells. C.
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Morphological changes in nuclei were examined after 72 h MSA treatment at 72hIC50
concentration. Hoechst stained nuclei were evaluated with a fluorescence microscope (200
and 400X, scale bar 3 μm) to detect increased condensation and margination of chromatin to
the nuclear envelope and the formation of apoptotic bodies (white arrows). Apoptotic bodies
were not observed in control condition. D. Cells were incubated with MSA, sodium selenite
and LY294002 at the indicated concentrations for 24 h and observed using an inverted phase
contrast microscope. E. Western blot analysis of total protein fractions of A549 cells. Protein
expression was determined by densitometry analysis using ImageJ software and is
represented as mean band intensity normalised to β-actin and related to untreated controls.
MSA apoptosis activation is represented by enhancement of Bax and cytosolic cytochrome c
expression, decrease of procaspase 3 levels and PARP cleavage (*, p < 0.05). Sodium
selenite induced changes in the same direction but to a significantly lower extent.
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Figure 3. MSA perturbs glycolysis, TCA cycle and nucleotide biosynthesis

Author Manuscript

A549 cells were grown in 0.2% [U-13C]-glucose in the presence or absence of 5 μM MSA
for 24 h. The polar metabolites were extracted in ice-cold 10% trichloroacetic acid and
analysed by 1D HSQC NMR (A, acquired at 14.1 T, 20°C) and GC-MS (B). A.
Representative 1D HSQC NMR spectrum. The abundance of the ribosyl unit of adenine
(13C-1′-AXP) and uracil (13C-1′-UXP) nucleotides was significantly attenuated 24 h after
MSA treatment, relative to the control treatment. B. The GC-MS analysis revealed reduced
synthesis of TCA cycle metabolites, [2-13C]-malate (Mal), [2-13C]-aspartate (Asp), [2-13C]glutamate (Glu) and [2-13C]-citrate (Cit), in addition to the glycolytic product, [3-13C]lactate (Lac). p values < 0.05 (*) were considered statistically significant.
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Figure 4. Nuclear translocation of GFP–FOXO following MSA treatment in U2foxRELOC cells

Author Manuscript

U2foxRELOC cells stably expressing GFP–FOXO fusion protein were treated with vehicle,
LY294002 (PI3K pathway inhibitor), MSA or sodium selenite for 6 hours. A. Representative
confocal microscopy images for U2foxRELOC cells. Left row (green) indicates the
subcellular location of FOXO3a-GFP. Celltracker location (red) identifies the cytoplasm.
Scale bar, 5 μm. B. Box and whiskers plot for the correlation between the nuclear and
cytoplasmic green fluorescence intensity. Higher values represent a higher FOXO3a-GFP
presence in the nucleus compared to the cytoplasm. Bar graph shows the percentage of the
cells in each condition exhibiting nuclear/cytoplasmic ratios of fluorescence intensity greater
than 3.5. MSA and LY294002 treatments display statistically significant differences (*) with
the control condition using a multiple rang test (Kruskal-Wallis test) with 99% confidence.
C. Viability assay with MSA in U2foxRELOC cells at 72 h. Exponentially growing cells
were treated with the indicated concentration of MSA for 72 h. The assay was carried out
using six replicates and repeated three times. Data are represented as mean ± SD.
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Figure 5. MSA induces GFP-FOXO3a nuclear translocation and increases endogenous nuclear
FOXO3a in A549 cells

Author Manuscript

A. Representative confocal microscopy images for A549 cells transfected with a FOXO3aGFP reporter plasmid and treated with vehicle, 20 μM LY294002 or 5 μM MSA for 6 h. Left
row (green) indicates the intracellular location of FOXO3a-GFP. Celltracker location (red)
identifies the cytoplasm. Scale bar, 5 μm. B. Box and whiskers plot for the correlation
between the nuclear and cytoplasmic green fluorescence intensity. Higher values indicate a
higher FOXO3a-GFP presence in the nucleus compared to the cytoplasm. Bar graph
represents the percentage of the cells in each condition displaying nuclear/cytoplasmic ratios
of fluorescence intensity greater than 1.5. MSA and LY294002 treatments present
statistically significant differences (*) with the control condition using a multiple rang test
(Kruskal-Wallis test) with 99% confidence. C. Western blots for the nuclear and cytoplasmic
fractions of A549 cells. Protein expression levels were quantified using ImageJ software and
are expressed as mean band intensity normalised to Lamin B (nuclear extract) or ERK 2
(cytosolic extract) and related to untreated controls. Endogenous nuclear FOXO3a levels
increase with 6 h MSA and LY294002 treatments whereas phosphorylated FOXO3a
cytoplasmic levels decrease (*, p < 0.05). D. mRNA levels of FOXO1 were analysed by
qRT-PCR. Cells were incubated with 5 μM MSA from 1 h up to 24 h. The graph bar
represents the expression of FOXO1 relative to control, which was assigned a value of 1.
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FOXO1 expression was significantly (*, p < 0.05) and progressively induced from 2 h to 24
h.
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Figure 6. MSA-induced G1 arrest and apoptosis are associated with Akt inhibition
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Total protein fractions of A549 cells were analysed by Western blot. Protein expression was
quantified by densitometric analysis using ImageJ software and is represented as mean band
intensity normalised to β-actin and related to untreated controls. MSA induces the
dephosphorylation of mTOR and Akt and its downstream target PRAS-40, the
phosphorylation of JNK, an increase of FOXO3a levels, a reduction of FOXM1 protein
expression and a G1 arrest represented by p27 accumulation. Differences between treated
and control groups were considered statistically significant at p < 0.05 (*).
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Figure 7. ROS detoxification by MSA treatment

A decrease in ROS levels was observed in MSA-treated A549 cells. This reduction was only
statistically significant after 24 and 48 h (*, p< 0.05). Cells treated with sodium selenite for
24 h presented similar ROS level to MSA-treated cells but significantly enhanced the
production of ROS in a time-dependent manner after 48 and 72 h incubations.
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Figure 8. Effects of FOXO3a knockdown on MSA activity
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U2OS and HEK293 cells were stably transfected with control shRNA (Ctrl) or constructs
expressing two different FOXO3a-specific shRNA sequences (FOXO3a #1 and FOXO3a
#2). A. Western blot analysis of total protein fractions of U2OS and HEK293 cells. β-actin
was used as a protein loading control. Sequence #1 exhibited the highest knockdown
efficiency. B and C. Viability assays after treatment with 1 μM MSA for 72 h in B. U2OS
shRNA transfected cells and C. HEK293 shRNA transfected cells. Data are expressed as
percentage of viability relative to untreated cells. D and E. Cell cycle analysis of 1 μM
MSA-treated cells for 72 h in D. U2OS shRNA transfected cells and E. HEK293 shRNA
transfected cells. Cell cycle analysis was conducted after propidium iodide staining. F and
G. Percentage of early apoptotic cells relative to untreated Ctrl shRNA cells obtained by
flow cytometry analysis of Annexin V-FITC staining and propidium iodide accumulation
after exposure of F. U2OS shRNA transfected cells and G. HEK293 shRNA transfected cells
to 1 μM MSA for 72 h. H and I. Intracellular ROS levels determined by flow cytometry after
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1 μM MSA incubation for 48 h of H. U2OS shRNA transfected cells and I. HEK293 shRNA
transfected cells. Results are expressed as percentage of mean fluorescent intensity relative
to untreated Ctrl shRNA cells. In all cases, values represent mean ± SD and statistically
significant differences between treated and control cells at p < 0.05 are indicated with an
asterisk (*).
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Figure 9. Effect of MSA on cell viability

A. Viability assays with MSA in NCI-H460, HCT116 and differentiated 3T3-L1 cells. B.
Comparison between the 72hIC50 values for the tested cell lines. The MSA concentration that
caused 50% of inhibition of cell viability at 72 h of treatment for the 3T3-L1 non-tumour
cell line was three to five times the value for all tumour cell lines analysed.
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Synergistic antiproliferative effect of MSA and cisplatin combination treatment

Author Manuscript

Cells were treated for 72 h at the indicated concentrations of MSA and cisplatin in a constant ratio. A. A549
cells, ratio 1:10. B. HCT116 cells, ratio 1:5. C. MCF7 cells, ratio 1:4. D. OVCAR3 cells, ratio 1:5. The CI
results obtained with CompuSyn software revealed a synergy (CI<1) in the antiproliferative effects of MSA
and cisplatin at each dose combination tested.
A. A549 cells, ratio 1:10.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.05

0.5

91.1 ± 1.8

0.570

0.1

1

78.9 ± 1.1

0.447

0.3

3

56.5 ± 2.0

0.631

0.5

5

41.1 ± 3.4

0.707

0.75

7.5

27.9 ± 2.6

0.751

1

10

17.3 ± 0.5

0.729

1.3

13

8.5 ± 0.5

0.663

1.5

15

4.2 ± 0.5

0.578

2

20

1.8 ± 0.5

0.595

B. HCT116 cells, ratio 1:5.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.75

3.75

74.5 ± 4.9

0.717

1

5

62.8 ± 3.9

0.667

1.5

7.5

45.1 ± 3.0

0.669

2

10

34.9 ± 3.9

0.725

2.5

12.5

26.0 ± 2.4

0.750

3

15

16.8 ± 2.1

0.716

3.5

17.5

11.0 ± 1.3

0.695

4

20

3.6 ± 0.7

0.517

5

25

2.6 ± 0.6

0.579

C. MCF7 cells, ratio 1:4.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.5

2

78.0 ± 1.2

0.275

0.75

3

74.6 ± 2.3

0.363

1

4

74.1 ± 2.1

0.476

1.5

6

70.2 ± 0.5

0.629

2

8

66.6 ± 0.1

0.753

2.5

10

49.5 ± 2.3

0.608

3

12

39.5 ± 3.2

0.575

3.5

14

19.9 ± 2.1

0.392

4

16

13.5 ± 1.4

0.350
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D. OVCAR3 cells, ratio 1:5.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.75

3.75

49.8 ± 2.9

0.431

1

5

36.7 ± 2.6

0.446

1.5

7.5

25.5 ± 2.3

0.523

2

10

18.4 ± 1.1

0.573

2.5

12.5

11.6 ± 0.7

0.555

3

15

7.4 ± 0.6

0.530

3.5

17.5

6.9 ± 0.4

0.597

4

20

4.6 ± 0.2

0.557

5

25

2.7 ± 0.6

0.538

Author Manuscript
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Table 2

Author Manuscript

Synergistic antiproliferative effect of MSA and carboplatin combination treatment.Cells were treated for 72 h
at the indicated concentrations of MSA and carboplatin in a constant ratio. A. A549 cells, ratio 1:6. B.
HCT116 cells, ratio 1:10. C. MCF7 cells, ratio 1:6. D. OVCAR3 cells, ratio 1:6. The CI results obtained with
CompuSyn software revealed a synergistic (CI<1) antiproliferative effect of MSA and carboplatin at each dose
combination tested.
A. A549 cells, ratio 1:6.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.5

3

81.2 ± 4.1

0.408

0.75

4.5

71.3 ± 5.2

0.642

1

6

61.2 ± 0.4

0.637

1.5

9

48.2 ± 1.4

0.775

2

12

30.7 ± 3.2

0.781

2.5

15

19.3 ± 0.9

0.626

3

18

12.8 ± 2.1

0.792

3.5

21

10.5 ± 1.3

0.816

4

24

8.1 ± 0.5

0.887

B. HCT116 cells, ratio 1:10.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.25

2.5

89 ± 1.3

0.306

0.5

5

77 ± 1.9

0.398

1

10

72 ± 0.2

0.661

1.5

15

55 ± 0.6

0.731

2

20

38 ± 3.4

0.711

2.5

25

22 ± 2.0

0.674

3

30

14 ± 0.6

0.692

3.5

35

12 ± 1.5

0.752

4

40

4 ± 2.8

0.608

5

50

2 ± 0.6

0.567

C. MCF7 cells, ratio 1:6.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.5

3

84.9 ± 5.4

0.295

0.75

4.5

70.3 ± 3.9

0.299

1

6

63.5 ± 5.0

0.347

1.5

9

55.2 ± 2.0

0.445

2

12

46.7 ± 4.3

0.510

2.5

15

36.1 ± 5.0

0.523

3

18

15.8 ± 4.2

0.381

3.5

21

13.4 ± 1.3

0.408

4

24

11.2 ± 0.7

0.424

5

30

8.7 ± 0.7

0.469
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D. OVCAR3 cells, ratio 1:6.

Author Manuscript

MSA (μM)

Cisplatin (μM)

Viability (%)

CI Value

0.75

4.5

85.1 ± 1.8

0.668

1

6

77.5 ± 5.1

0.697

1.5

9

66.9 ± 0.5

0.908

2

12

44.4 ± 0.0

0.862

2.5

15

37.1 ± 1.0

0.966

3

18

24.7 ± 0.6

0.937

3.5

21

14.9 ± 0.1

0.874

4

24

6.5 ± 2.0

0.719

5

30

3.2 ± 0.6

0.686
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Author Manuscript
Author Manuscript
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